Eosinophilic gastrointestinal diseases make a name for themselves: A new consensus statement with updated nomenclature - 04/08/22
Doi : 10.1016/j.jaci.2022.05.012
Benjamin L. Wright, MD a, b, ⁎ 
, Justin T. Schwartz, MD, PhD c, d, Melanie A. Ruffner, MD, PhD e, f, Glenn T. Furuta, MD g, h, Nirmala Gonsalves, MD i, Evan S. Dellon, MD, MPH j, Seema S. Aceves, MD, PhD k, l
, Justin T. Schwartz, MD, PhD c, d, Melanie A. Ruffner, MD, PhD e, f, Glenn T. Furuta, MD g, h, Nirmala Gonsalves, MD i, Evan S. Dellon, MD, MPH j, Seema S. Aceves, MD, PhD k, l a Division of Allergy, Asthma and Clinical Immunology, Department of Medicine, Mayo Clinic Arizona, Scottsdale, Ariz
b Section of Allergy and Immunology, Division of Pulmonology, Phoenix Children’s Hospital, Phoenix, Ariz
c Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Philadelphia, Pa
d Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio
e Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa
f Division of Allergy and Immunology, Children's Hospital of Philadelphia, Pa
g Digestive Health Institute, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital Colorado, Aurora, Colo
h Gastrointestinal Eosinophilic Diseases Program, Department of Pediatrics, Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, Colo
i Division of Gastroenterology and Hepatology, Northwestern University, Feinberg School of Medicine, Chicago, Ill
j Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC
k Division of Allergy and Immunology, Department of Pediatrics and Medicine, University of California, San Diego, Calif
l Rady Children's Hospital, San Diego, Calif
∗Corresponding author: Benjamin Wright, MD, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259.Mayo Clinic13400 E Shea BlvdScottsdaleAZ85259
Key words : Eosinophilic esophagitis, eosinophilic gastritis, eosinophilic duodenitis, eosinophilic enteritis, eosinophilic colitis, nomenclature
Le texte complet de cet article est disponible en PDF.
| Supported by grant U54AI117804 from the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR), which is part of the Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Disease Research. The CEGIR is also supported by patient advocacy groups, including the American Partnership for Eosinophilic Disorders, the Campaign Urging Research for Eosinophilic Diseases, and the Eosinophilic Family Coalition. As a member of the RDCRN, the CEGIR is also supported by its data management and coordinating center (grant U2CTR002818). |
|
| Disclosure of potential conflict of interest: B. L. Wright has received research funding from Allakos. G. T. Furuta is the founder of EnteroTrack and has received research funding from Holoclara, Arena, and the National Institutes of Health. N. Gonsalves has served as a consultant for Allakos, AstraZeneca, Knopp, AbbVie, Regeneron-Sanofi, and Nutricia; served on the speakers bureau for Takeda; received royalties from UpToDate and Abonia; and served as a consultant for Takeda. E. S. Dellon has received research funding from Adare/Ellodi, Allakos, Arena, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, and Shire/Takeda; served as a consultant for Abbott, AbbVie, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, InveniAI, Landos, LucidDx, Morphic, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Ali-mentiv, Salix, Sanofi, Shire/Takeda, and Target RWE; and received educational grant support from Allakos, Banner, and Holoclara. Seema S. Aceves is coinventor of oral viscous budesonide, which is University of California San Diego–patented and Takeda-licensed, and has served as a consultant for Regeneron and AstraZeneca. The remaining authors declare that they have no relevant conflicts of interest. |
© 2022
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 150 - N° 2
P. 291-293 - août 2022 Retour au numéro
Article précédent
- Chronic rhinosinusitis: Future treatments and unmet needs
- Sneha Giri, Alexander L. Schneider, Bruce K. Tan
- Blood endotypic signature in atopic dermatitis: The challenge in personalized medicine
- Tom C. Chan, Chia-Yu Chu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?